The GUARD-AF trial will allow us to look at both the benefits and the risks of screening for atrial fibrillation and the reduction of stroke, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.
The GUARD-AF trial will allow us to look at both the benefits and the risks of screening for atrial fibrillation and the reduction of stroke, said Roland Chen, MD, MS, vice president and head of clinical development for innovative medicines at Bristol-Myers Squibb.
Transcript
What are some of the primary endpoints being sought by the GUARD-AF trial? How are healthcare claims being utilized to distinguish evidence on health outcomes associated with atrial fibrillation?
The primary efficacy endpoint in GUARD-AF is actually stroke that leads to a hospital evaluation. The primary safety endpoint in GUARD-AF is bleeding that leads to hospitalization. So, GUARD-AF will actually allow us to look at both the benefits and the risks of screening for atrial fibrillation and the reduction of stroke. Healthcare claims are important in this study, because healthcare claims will actually be used to identify the occurrence of these primary endpoints because these patients are receiving Medicare as their health insurance. So this study, although it's a clinical study where patients are randomized, is actually being conducted in a real world setting. So, healthcare claims will be an important part of this pragmatic trial.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More